Losartan Potassium (Cas No 124750-99-8) EU/USP





TAJLTSP-LNY44587

Losartan Potassium CAS NO. 124750-99-8

Losartan potassium is available as per USP specifications

Synonyms 2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol monopotassium salt

Molecular Formula C22H22CIKN6OK

Molecular Weight 461.01

CAS Registry Number: 124750-99-8

Optional Information

- HS Code: 3006 Pharmaceutical Goods

Payment: TTDelivery: 3 daysOrigin: ChinaMinimum Order: 1gInspection: 99%

K⁺ N CH

Packing: Export worthy packing

Material Safety Data Sheet: Losartan potassium MSDS available on request

Availability: For your requirements of evaluation, Pilots and Commercial procurement

Drug Master File: Losartan potassium, USDMF Available, EDMF available, AIFA ITALY EUGMP approved, KDMF approval awaited

Packing: 5kg/drum,25kg/drum

Delivery Date: stock cargo for prompt shipment.

Specification

Appearance: white or off-white crystalline powder.

Assay: Not less than 99%

Standard: complies with EU/USP standard

Application: Antihypertensive API

Origin: INDIA

Losartan is being studied for use in the treatment of the 20% of breast cancer.

We have experience in Exporting and Manufacturing of all Countries and Overseas medicines in quick reliable manner and we are very interested to start collaboration with your company or organisation!



2004 - 2010 Taj Pharmaceuticals Limited. All rights reserved

Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider. Active Pharmaceutical Ingredients manufacturer, exporter, drug ingredients, pharmaceuticals, India Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to

*** CANCER DRUG